← Issue №14/ week of Oct 4, 2026/IBD

Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD systematic review · n=54,258 · Oct 1, 2026 · Aliment Pharm Ther · IF 6.7

Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies.

New evidencesystematic reviewbiologicsJAK inhibitors
Clinical takeawayConsider that RCTs of advanced therapies for IBD rarely include patients with DTT-IBD, and subgroup-specific efficacy data for this population are lacking. Discuss trial limitations and extrapolation risks when recommending advanced therapies to DTT-IBD patients.
What it foundOnly 16.1% of UC trials and 10.5% of CD trials included patients with DTT-IBD (exposure to ≥ 2 ATs with different mechanisms), and DTT-IBD patients accounted for 16.2% of UC and 22.4% of CD study populations.
ContextChallenges current practice by highlighting the limited representation of DTT-IBD patients in RCTs, despite their clinical relevance. Prior evidence assumes generalizability of trial results to all IBD patients.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Parigi TL … Danese S · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues